Trial Profile
Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection: a phase 1b/2a trial (TEACH)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lefitolimod (Primary)
- Indications HIV-1 infections
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms TEACH
- 29 Mar 2019 Results published in the AIDS
- 07 Mar 2018 Results assessing safety and immunogenicity presented at the 25th Conference on Retroviruses and Opportunistic Infections
- 07 Mar 2018 Results presented at the 25th Conference on Retroviruses and Opportunistic Infections